Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 6 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 2 |
| Antidepressants Market to 2018 - Introduction | 12 | 1 |
| Market Overview | 13 | 15 |
| Introduction | 13 | 1 |
| Classification of Antidepressants | 14 | 1 |
| Selective Serotonin Reuptake Inhibitors | 15 | 1 |
| Serotonin-Norepinephrine Reuptake Inhibitors | 15 | 1 |
| Noradrenergic and Specific Serotonergic Antidepressants | 15 | 1 |
| Norepinephrine Reuptake Inhibitors | 16 | 1 |
| Norepinephrine-Dopamine Reuptake Inhibitors | 16 | 1 |
| Norepinephrine-Dopamine Disinhibitors | 16 | 1 |
| Serotonin Antagonist and Reuptake Inhibitors | 16 | 1 |
| Tricyclic Antidepressants | 16 | 1 |
| Tetracyclic Antidepressants | 17 | 1 |
| Monoamine Oxidase Inhibitors | 17 | 1 |
| Others | 18 | 1 |
| Adverse Effects | 18 | 1 |
| Major Marketed Products in the Antidepressants Therapy Area | 18 | 2 |
| Future Developments | 20 | 1 |
| Revenue | 21 | 2 |
| Annual Cost of Therapy | 23 | 1 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Drivers and Restraints of the Antidepressants Market | 26 | 1 |
| Drivers | 26 | 1 |
| Increase in Prevalence Leads to Rise in Patient Population | 26 | 1 |
| Novel Multimodal Therapies Can Change the Future Market Scenario | 26 | 1 |
| Unmet Clinical Needs Pose a Steady Opportunity for R&D Initiatives and Growth of Existing Therapies | 26 | 1 |
| Increase in Awareness Levels of Disease States and Etiology, and Social Changes | 26 | 1 |
| Restraints | 27 | 1 |
| Low Diagnosis and Prescription Rates | 27 | 1 |
| Non-Pharmacological Therapies Preferred over Pharmacological Therapies | 27 | 1 |
| Poor Efficacy and Safety Profiles Restrain Usage | 27 | 1 |
| Repeated Drug Failures in Clinical Trials Has Put Substantial Pressure on Companies in This Area | 27 | 1 |
| Availability of Generics and Weak Pipeline | 27 | 1 |
| Therapeutic Landscape | 28 | 38 |
| Antidepressants Market for Major Depressive Disorder | 28 | 1 |
| Introduction | 28 | 2 |
| Revenue and Forecasts | 30 | 1 |
| Annual Cost of Therapy | 31 | 1 |
| Treatment Usage Patterns | 32 | 1 |
| Diseased Population | 33 | 1 |
| Diagnosed Population | 33 | 1 |
| Prescription Population | 33 | 1 |
| Geographical Segmentation | 33 | 1 |
| The US | 33 | 1 |
| EU5 | 33 | 1 |
| Japan | 34 | 1 |
| Drivers and Restraints for the Antidepressants Market for Major Depressive Disorder | 35 | 1 |
| Drivers | 35 | 1 |
| New Launches | 35 | 1 |
| Improvements in Awareness and Resultant Diagnosis Levels Will Drive the Market | 35 | 1 |
| Substantial Unmet Need Increases Market Potential | 35 | 1 |
| Restraints | 35 | 1 |
| Noncompliance with Drug Therapy and Antidepressant Side Effects | 35 | 1 |
| Poor Diagnostic Tools for the Treatment of Major Depressive Disorder | 36 | 1 |
| Limitations in the Efficacy of Existing Drugs Can Potentially Lead to Low Prescription Rates | 36 | 1 |
| Inadequate Knowledge of Disease Progression Hinders Development of Drugs with Better Efficacy | 36 | 1 |
| Genericization Leading to a Decline in the Annual Cost of Therapy | 36 | 1 |
| Alternative Therapy for MDD | 36 | 1 |
| Antidepressants Market for Obsessive-Compulsive Disorder | 37 | 1 |
| Introduction | 37 | 2 |
| Revenue and Forecasts | 39 | 1 |
| Annual Cost of Therapy | 40 | 1 |
| Treatment Usage Patterns | 41 | 1 |
| Diseased Population | 42 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Geographical Segmentation | 42 | 1 |
| The US | 42 | 1 |
| EU5 | 43 | 1 |
| Japan | 43 | 1 |
| Drivers and Restraints for the Antidepressants Market for Obsessive-Compulsive Disorder | 44 | 1 |
| Drivers | 44 | 1 |
| Scope for New Entrants Novel Multimodal Therapies Can Change the Future Market Scenario | 44 | 1 |
| Chronic Nature of the Condition | 44 | 1 |
| More Active Treatment-Seeking Behavior to Drive Increase in Patient Volumes | 44 | 1 |
| Restraints | 44 | 1 |
| Problems with Diagnosis Hinder Market Growth | 44 | 1 |
| Poor Efficacy and Lack of Treatment Options | 44 | 1 |
| Antidepressants Market for Generalized Anxiety Disorder | 45 | 1 |
| Introduction | 45 | 1 |
| Revenue and Forecasts | 46 | 2 |
| Annual Cost of Therapy | 48 | 1 |
| Treatment Usage Patterns | 49 | 2 |
| Diseased Population | 51 | 1 |
| Diagnosed Population | 51 | 1 |
| Prescription Population | 51 | 1 |
| Geographical Segmentation | 51 | 1 |
| The US | 52 | 1 |
| EU5 | 52 | 1 |
| Japan | 52 | 2 |
| Drivers and Restraints for the Antidepressants Market for Generalized Anxiety Disorder | 54 | 1 |
| Drivers | 54 | 1 |
| High Prevalence | 54 | 1 |
| Unmet Needs Related to Safety and Efficacy | 54 | 1 |
| Restraints | 54 | 1 |
| Poor Diagnosis Rates | 54 | 1 |
| Psychotherapy Preferred over Pharmacotherapy | 54 | 1 |
| Antidepressants Market for Panic Disorder | 55 | 1 |
| Introduction | 55 | 3 |
| Revenue and Forecasts | 58 | 1 |
| Annual Cost of Therapy | 59 | 1 |
| Treatment Usage Patterns | 60 | 1 |
| Diseased Population | 61 | 1 |
| Diagnosed Population | 61 | 1 |
| Prescription Population | 61 | 1 |
| Geographical Segmentation | 62 | 1 |
| The US | 62 | 1 |
| EU5 | 62 | 1 |
| Japan | 62 | 2 |
| Drivers and Restraints for the Antidepressants Market for Panic Disorder | 64 | 1 |
| Drivers | 64 | 1 |
| Growing Prevalence | 64 | 1 |
| Unmet Needs Related to Safety and Efficacy | 64 | 1 |
| Restraints | 64 | 1 |
| Lack of Awareness and Problems with Diagnosis | 64 | 1 |
| Low Prescription Rates | 65 | 1 |
| Safety and Efficacy Issues | 65 | 1 |
| Geographical Landscape | 66 | 13 |
| The US | 67 | 1 |
| Revenue and Forecasts | 67 | 2 |
| Annual Cost of Therapy | 69 | 1 |
| Treatment Usage Patterns | 70 | 1 |
| Diseased Population | 71 | 1 |
| Diagnosed Population | 71 | 1 |
| Prescription Population | 71 | 1 |
| EU5 | 72 | 1 |
| Revenue and Forecasts | 72 | 1 |
| Annual Cost of Therapy | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Diseased Population | 75 | 1 |
| Diagnosed Population | 75 | 1 |
| Prescription Population | 75 | 1 |
| Japan | 75 | 1 |
| Revenue and Forecasts | 75 | 1 |
| Annual Cost of Therapy | 76 | 1 |
| Treatment Usage Patterns | 77 | 1 |
| Diseased Population | 78 | 1 |
| Diagnosed Population | 78 | 1 |
| Prescription Population | 78 | 1 |
| Pipeline Analysis | 79 | 8 |
| Introduction | 79 | 1 |
| Summary of the Current Antidepressants R&D Pipeline | 79 | 3 |
| Profiles of Key Late-Stage Drugs in the Antidepressants Market | 82 | 1 |
| Vortioxetine (Lu AA21004) | 82 | 1 |
| Overview | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| R&D Progress/Latest Activity | 82 | 1 |
| Clinical Trial Summaries | 82 | 1 |
| Licensing and Collaboration | 83 | 1 |
| F-2695 (levomilnacipran) | 83 | 1 |
| Overview | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress/Latest Activity | 83 | 1 |
| LY-2216684 (edivoxetine) | 84 | 1 |
| Overview | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| R&D Progress/Latest Activity | 84 | 1 |
| OPC-34712 | 84 | 1 |
| Overview | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| R&D Progress/Latest Activity | 84 | 1 |
| EB-1010/Amitifadine | 85 | 1 |
| Overview | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress/Latest Activity | 85 | 1 |
| PNB01 | 86 | 1 |
| Overview | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress/Latest Activity | 86 | 1 |
| Competitive Landscape | 87 | 9 |
| Competitive Profiling | 87 | 1 |
| H. Lundbeck | 87 | 1 |
| Company Overview | 87 | 1 |
| Business Description | 87 | 1 |
| Financial Overview | 87 | 1 |
| SWOT profile | 88 | 1 |
| AstraZeneca | 88 | 1 |
| Company Overview | 88 | 1 |
| Business Description | 88 | 1 |
| SWOT Profile | 89 | 1 |
| Eli Lilly and Company | 89 | 1 |
| Company Overview | 89 | 1 |
| Business Description | 89 | 1 |
| Financial Overview | 90 | 1 |
| SWOT Profile | 90 | 1 |
| Forest Laboratories | 90 | 1 |
| Company Overview | 90 | 1 |
| Business Description | 90 | 1 |
| Financial Overview | 91 | 1 |
| SWOT Profile | 91 | 1 |
| Pfizer Inc. | 92 | 1 |
| Company Overview | 92 | 1 |
| Business Description | 92 | 1 |
| Financial Overview | 92 | 1 |
| SWOT Profile | 93 | 1 |
| GlaxoSmithKline | 93 | 1 |
| Company Overview | 93 | 1 |
| Business Description | 93 | 1 |
| Financial Overview | 93 | 1 |
| SWOT Profile | 94 | 1 |
| Bristol-Myers Squibb Company | 94 | 1 |
| Company Overview | 94 | 1 |
| Business Description | 94 | 1 |
| Financial Overview | 94 | 1 |
| SWOT Profile | 95 | 1 |
| Strategic Consolidations | 96 | 6 |
| Merger and Acquisition Deals | 96 | 1 |
| Paladin Labs Completes Acquisition of Labopharm | 96 | 1 |
| High River Acquires 6.5% Stake in Forest Laboratories | 96 | 1 |
| Forest Laboratories Completes Acquisition of Clinical Data | 96 | 1 |
| Azur Pharma Completes Merger with Jazz Pharmaceuticals in All Stock Transaction | 97 | 1 |
| Nuvo Research Acquires ZARS Pharma | 97 | 1 |
| Sun Pharmaceutical Acquires Remaining 24% Stake of Caraco Pharmaceutical | 98 | 1 |
| Licensing Agreements | 98 | 1 |
| Labopharm Enters into Licensing Agreement with Angelini Group for OLEPTRO | 98 | 1 |
| Omeros Expands Licensing Agreement with Daiichi Sankyo | 98 | 1 |
| Jazz Pharmaceuticals Enters into Sub-Licensing Agreement with Anchen | 98 | 1 |
| AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept | 99 | 1 |
| Indevus Pharmaceuticals Enters into Licensing Agreement with Teva Pharmaceutical | 99 | 1 |
| Impax Laboratories Enters into Licensing Agreement with Wyeth | 99 | 1 |
| Mylan Enters into Licensing Agreement with GlaxoSmithKline | 99 | 1 |
| Tikvah Therapeutics Signs Licensing Agreement with Therapade Technologies | 99 | 1 |
| GlaxoSmithKline Signs an Agreement with Fabre-Kramer Pharmaceuticals | 100 | 1 |
| Jazz Pharmaceuticals Enters into Licensing Agreement with Solvay | 100 | 1 |
| Targacept Enters into Licensing Agreement with Yale University | 100 | 1 |
| Co-Development Deals | 100 | 1 |
| Lundbeck Enters into Co-Development Agreement with Otsuka Pharmaceutical | 100 | 1 |
| Eli Lilly Terminates Co-Development Agreement with Boehringer Ingelheim | 101 | 1 |
| Lundbeck Enters into Co-Development Agreement with Takeda | 101 | 1 |
| Appendix | 102 | 9 |
| Market Definitions | 102 | 1 |
| Abbreviations | 102 | 2 |
| Sources | 104 | 1 |
| Research Methodology | 105 | 2 |
| Coverage | 105 | 1 |
| Secondary Research | 105 | 1 |
| Primary Research | 106 | 1 |
| Therapeutic Landscape | 107 | 3 |
| Epidemiology-based Forecasting | 107 | 2 |
| Market Size by Geography | 109 | 1 |
| Geographical Landscape | 110 | 1 |
| Pipeline Analysis | 110 | 1 |
| Competitive Landscape | 110 | 1 |
| Expert Panel Validation | 110 | 1 |
